Search Within

GDMT, Medicine

Formats
  1. Journal Article (927)
  2. Meeting Abstract (829)
  3. Review (48)
  4. Book Section (38)
  5. Editorial (29)
  6. Guidelines (19)
  7. Correspondence (7)
  8. Research Letter (1)
Groups
  1. Gynecology Disease Management Team (1898)
  2. Department of Medicine (1888)
  3. Solid Tumor Oncology Division (1887)
  4. Gynecologic Medicine Service (1847)
  5. Surgery (582)
  6. GDMT, Surgery (465)

More Groups

People
  1. Carol Aghajanian (613)
  2. Martee Hensley (290)
  3. Nadeem Abu-Rustum (279)
  4. Roisin O'Cearbhaill (272)
  5. Vicky Makker (267)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (61)
  2. 2024 (159)
  3. 2023 (165)
  4. 2022 (196)
  5. 2021 (146)
  6. 2020 (173)

More Years

Publications
  1. Journal of Clinical Oncology (417)
  2. Gynecologic Oncology (416)
  3. International Journal of Gynecological Cancer (151)
  4. Annals of Oncology (106)
  5. Clinical Cancer Research (64)
  6. Cancer (37)

More Publications

Publishers
  1. Elsevier Inc. (496)
  2. American Society of Clinical Oncology (449)
  3. Lippincott Williams & Wilkins (176)
  4. American Association for Cancer Research (139)
  5. Oxford University Press (128)
  6. Nature Publishing Group (73)

More Publishers

Results (1898)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers
    Journal Article

    Moufarrij, S.; O'Cearbhaill, R. E.; Zhou, Q.; Iasonos, A.; Mantha, S.; Zwicker, J.; Wilkins, C. R.
    Gynecologic Oncology Reports (2024)

    Fulltext@MSK | Save
  • Developing novel genomic risk stratification models in soft tissue and uterine leiomyosarcoma
    Journal Article

    Dermawan, J. K.; Chiang, S.; Singer, S.; Jadeja, B.; Hensley, M. L.; Tap, W. D.; Movva, S.; Maki, R. G.; Antonescu, C. R.
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: A case series
    Journal Article

    Sia, T. Y.; Wan, V.; Finlan, M.; Zhou, Q. C.; Iasonos, A.; Zivanovic, O.; Sonoda, Y.; Chi, D. S.; Long Roche, K.; Jewell, E.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results
    Journal Article

    Rappaport, A. R.; Kyi, C.; Lane, M.; Hart, M. G.; Johnson, M. L.; Henick, B. S.; Liao, C. Y.; Mahipal, A.; Shergill, A.; Spira, A. I.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Expanding the spectrum of NR4A3 fusion–positive gynecologic leiomyosarcomas
    Journal Article

    Momeni-Boroujeni, A.; Mullaney, K.; DiNapoli, S. E.; Leitao, M. M. Jr; Hensley, M. L.; Katabi, N.; Allison, D. H. R.; Park, K. J.; Antonescu, C. R.; Chiang, S.
    Modern Pathology (2024)

    Fulltext@MSK | Save
  • Management challenges in low-grade serous ovarian cancer with a BRCA mutation
    Journal Article

    Sanchez-Lorenzo, L.; Sancho, L.; Iscar, T.; Grisham, R.; Chiva, L.
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016
    Journal Article

    Gien, L. T.; Enserro, D. M.; Block, M. S.; Waggoner, S.; Duska, L. R.; Wahner-Hendrickson, A. E.; Thaker, P. H.; Backes, F.; Kidd, M.; Muller, C. Y.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer
    Journal Article

    Ehmann, S.; Lam, C.; Zhou, Q.; Iasonos, A.; Grisham, R. N.; Tew, W. P.; O'Cearbhaill, R. E.; Long Roche, K.; Zivanovic, O.; Sonoda, Y.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Analysis of East Asia subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician’s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer
    Journal Article

    Yonemori, K.; Fujiwara, K.; Hasegawa, K.; Yunokawa, M.; Ushijima, K.; Suzuki, S.; Shikama, A.; Minobe, S.; Usami, T.; Kim, J. W.; more...
    Journal of Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • FcgRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment
    Journal Article

    Knorr, D. A.; Blanchard, L.; Leidner, R. S.; Jensen, S. M.; Meng, R.; Jones, A.; Ballesteros-Merino, C.; Bell, R. B.; Baez, M.; Marino, A.; more...
    Cancer Immunology Research (2024)

    Fulltext@MSK | Save